SCHEMBL4494479

SCHEMBL4494479

CCOC(=O)CN1N=C(c2ccccc2)c2ccccc2N(CC(=O)C2CCCC2)C1=O

nearest known ligand 0.50

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CCKBR P32239 10/20 0.50
CCKAR P32238 8/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4505312 0.87 CCKBR (0.52) CCKBRCCKAR
SCHEMBL4494879 0.85 CCKBR (0.50) CCKBRCCKAR
SCHEMBL4494470 0.85 CCKBR (0.61) CCKBRCCKAR
SCHEMBL4558000 0.83 CCKBR (0.66) CCKBRCCKAR
SCHEMBL15327829 0.83 CCKBR (0.49) CCKBRCCKAR
SCHEMBL3911566 0.77 CCKBR (0.55) CCKBRCCKAR
SCHEMBL3980978 0.76 CCKBR (0.53) CCKBRCCKAR
SCHEMBL3920920 0.76 CCKBR (0.61) CCKBRCCKAR
SCHEMBL4505281 0.75 CCKBR (0.43) CCKBRCCKAR
SCHEMBL3909523 0.75 CCKBR (0.53) CCKBRCCKAR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1948624-B1 PROCESS FOR THE PREPARATION OF BENZO[E][1,2,4]TRIAZEPIN-2-ONE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2013-10-23 EP claimed
US-7582753-B2 Process for the preparation of benzotriazepine derivatives JANSSENPHARMACEUTICA, NV (BE) 2009-09-01 US claimed
EP-1948624-A2 PROCESS FOR THE PREPARATION OF BENZO[E][1,2,4]TRIAZEPIN-2-ONE DERIVATIVES Janssen Pharmaceutica, N.V. (BE) 2008-07-30 EP claimed
WO-2007035430-A2 PROCESS FOR THE PREPARATION OF BENZO [E] [1,2,4] TRIAZEPIN-2-ONE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2007-03-29 WO claimed
US-20070066819-A1 PROCESS FOR THE PREPARATION OF BENZOTRIAZEPINE DERIVATIVES JANSSEN PHARMACUETICA N.V., (BE) 2007-03-22 US claimed
EP-1948624-B1 PROCESS FOR THE PREPARATION OF BENZO[E][1,2,4]TRIAZEPIN-2-ONE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2013-10-23 EP disclosed
US-7582753-B2 Process for the preparation of benzotriazepine derivatives JANSSENPHARMACEUTICA, NV (BE) 2009-09-01 US disclosed
EP-1948624-A2 PROCESS FOR THE PREPARATION OF BENZO[E][1,2,4]TRIAZEPIN-2-ONE DERIVATIVES Janssen Pharmaceutica, N.V. (BE) 2008-07-30 EP disclosed
WO-2007035430-A2 PROCESS FOR THE PREPARATION OF BENZO [E] [1,2,4] TRIAZEPIN-2-ONE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2007-03-29 WO disclosed
US-20070066819-A1 PROCESS FOR THE PREPARATION OF BENZOTRIAZEPINE DERIVATIVES JANSSEN PHARMACUETICA N.V., (BE) 2007-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070066819-A1 PROCESS FOR THE PREPARATION OF BENZOTRIAZEPINE DERIVATIVES CCKBR, CCKAR, GRPR CCKBR 1/4885CCKAR 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.